Role of μ-opioid receptor reserve and μ-agonist efficacy as determinants of the effects of μ-agonists on intracranial self-stimulation in rats

Behavioural Pharmacology

Volumn 23, Issue 7, 2012, Pages 678-692

  Altarifi, Ahmad A ^a,b   Miller, Laurence L ^a   Stevens Negus, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

drug abuse; efficacy; intracranial self stimulation; morphine; opioid; rat

Indexed keywords

BETA FUNALTREXAMINE; BUPRENORPHINE; FENTANYL; HYDROCODONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALTREXONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRACRANIAL SELF STIMULATION; MALE; MORPHINE TOLERANCE; NONHUMAN; RAT; RECEPTOR DENSITY; SELF STIMULATION;

ANIMALS; BRAIN; DRUG TOLERANCE; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; REINFORCEMENT SCHEDULE; SELF STIMULATION;

EID: 84866321680     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328358593c     Document Type: Article

References (42)

1. Altarifi AA, Negus SS (2011). Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence. Behav Pharmacol 22:663-673.
2. Bardo MT, Gehrke BJ, Shortridge BE, Rauhut AS (2003). Effects of beta-funaltrexamine and naloxonazine on single-trial morphine-conditioned place preference and locomotor activity. Pharmacol Biochem Behav 74:617-622. (Pubitemid 36126540)
3. Broekkamp CL, Van Den Bogaard JH, Heijnen HJ, Rops RH, Cools AR, Van Rossum JM (1976). Separation of inhibiting and stimulating effects of morphine on self-stimulation behaviour by intracerebral microinjections. Eur J Pharmacol 36:443-446.
4. Carlezon WA Jr., Wise RA (1993). Morphine-induced potentiation of brain stimulation reward is enhanced by mk-801. Brain Res 620:339-342. (Pubitemid 23231668)
5. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A (2007). The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (radars). Pain Med 8:157-170.
6. Comer SD, Burke TF, Lewis JW, Woods JH (1992). Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther 262:1051-1056.
7. Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ (2000). Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl) 150:430-442. (Pubitemid 30470222)
8. Craft RM, Stoffel EC, Stratmann JA (2001). Effects of chronic morphine treatment on responding for intracranial stimulation in female versus male rats. Exp Clin Psychopharmacol 9:198-208. (Pubitemid 32852321)
9. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 168:347-358. (Pubitemid 36920920)
10. Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon WA Jr, Negus SS (2009). The selective non-peptidic delta opioid agonist snc80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol 604:58-65.
11. Easterling KW, Holtzman SG (1997). Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists. J Pharmacol Exp Ther 281:188-199. (Pubitemid 27203068)
12. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994). Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637. (Pubitemid 24382680)
13. Esposito RU, Perry W, Kornetsky C (1980). Effects of d-amphetamine and naloxone on brain stimulation reward. Psychopharmacology (Berl) 69:187-191. (Pubitemid 10069543)
14. Hughes PH, Rieche O (1995). Heroin epidemics revisited. Epidemiol Rev 17:66-73.
15. Jha SH, Knapp CM, Kornetsky C (2004). Effects of morphine on brain-stimulation reward thresholds in young and aged rats. Pharmacol Biochem Behav 79:483-490. (Pubitemid 39576165)
16. Koob GF, Spector NH, Meyerhoff JL (1975). Effects of heroin on lever pressing for intracranial self-stimulation, food and water in the rat. Psychopharmaco-logia 42:231-234.
17. Kornetsky C, Esposito RU (1979). Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473-2476. (Pubitemid 10249276)
18. Lorens SA, Mitchell CL (1973). Influence of morphine on lateral hypothalamic self-stimulation in the rat. Psychopharmacologia 32:271-277.
19. Martin TJ, Dworkin SI, Smith JE (1993). Effects of intracerebroventricular administration of beta-funaltrexamine on [3h]damgo binding to rat brain sections. J Pharmacol Exp Ther 267:506-514. (Pubitemid 23325046)
20. Martin TJ, Sim LJ, Selley DE, Demontis MG, Childers SR (1997). Effects of intracerebroventricular administration of beta-funaltrexamine on damgo-stimulated [35s]gtp-gamma-s binding in rat brain sections. Synapse 27:177-182. (Pubitemid 27430667)
21. Martini L, Whistler JL (2007). The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17:556-564.
22. Morgan D, Cook CD, Smith MA, Picker MJ (1999). An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg 88:407-413. (Pubitemid 29070208)
23. Negus SS, Mello NK (1999). Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. J Pharmacol Exp Ther 290:1132-1140. (Pubitemid 29400253)
24. Negus SS, Brandt MR, Gatch MB, Mello NK (2003). Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine. Drug Alcohol Depend 70:17-27. (Pubitemid 36385150)
25. Negus SS, Morrissey EM, Rosenberg M, Cheng K, Rice KC (2010). Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) 210:149-159.
26. Pereira Do Carmo G, Stevenson GW, Carlezon WA, Negus SS (2009). Effects of pain-and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 144:170-177.
27. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994). Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45:330-334.
28. Sannerud CA, Young AM (1986). Modification of morphine tolerance by behavioral variables. J Pharmacol Exp Ther 237:75-81. (Pubitemid 16116346)
29. Schaefer GJ, Michael RP (1983). Morphine withdrawal produces differential effects on the rate of lever-pressing for brain self-stimulation in the hypothalamus and midbrain in rats. Pharmacol Biochem Behav 18:571-577. (Pubitemid 13128875)
30. Schuster CR, Dockens WS, Woods JH (1966). Behavioral variables affecting the development of amphetamine tolerance. Psychopharmacologia 9:170-182.
31. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR (1997). Mu-opioid receptor-stimulated guanosine-5-o-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51:87-96. (Pubitemid 27049549)
32. Selley DE, Liu Q, Childers SR (1998). Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35s]gtp gamma S binding in mmor-cho cells and rat thalamus. J Pharmacol Exp Ther 285:496-505. (Pubitemid 28237424)
33. Sim LJ, Selley DE, Dworkin SI, Childers SR (1996). Effects of chronic morphine administration on mu opioid receptor-stimulated [35s]gtpgammas autoradio-graphy in rat brain. J Neurosci 16:2684-2692.
34. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (2004). Activation of g-proteins by morphine and codeine congeners: insights to the relevance of o-and n-demethylated metabolites at mu-and delta-opioid receptors. J Pharmacol Exp Ther 308:547-554. (Pubitemid 38134216)
35. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. (2004). Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psycho-pharmacology (Berl) 172:463-470. (Pubitemid 38650984)
36. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. (1998). Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466.
37. Walker EA, Zernig G, Woods JH (1995). Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345-1352.
38. Walker EA, Zernig G, Young AM (1998). In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology (Berl) 136:15-23. (Pubitemid 28097516)
39. Walker EA, Tiano MJ, Benyas SI, Dykstra LA, Picker MJ (1999). Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psycho-pharmacology (Berl) 144:45-53. (Pubitemid 29242669)
40. Ward SJ, Portoghese PS, Takemori AE (1982). Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther 220:494-498. (Pubitemid 12152158)
41. Wise RA (1998). Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13-22. (Pubitemid 28353753)
42. Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH (1994). In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57-65. (Pubitemid 24143235)